{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:42:42Z","timestamp":1793292162452,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00259-022-05778-w","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T06:08:15Z","timestamp":1649225295000},"page":"3581-3592","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 \u03b1-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4273-040X","authenticated-orcid":false,"given":"Ismaheel O.","family":"Lawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Morgenstern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariza","family":"Vorster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Knoesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johncy","family":"Mahapane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khanyisile N.","family":"Hlongwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letjie C.","family":"Maserumule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honest","family":"Ndlovu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet D.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gbenga O.","family":"Popoola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kgomotso M. G.","family":"Mokoala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Mdlophane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Bruchertseifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2806-0625","authenticated-orcid":false,"given":"Mike M.","family":"Sathekge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,6]]},"reference":[{"key":"5778_CR1","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2967\/jnumed.119.230318","volume":"61","author":"KL Pomykala","year":"2020","unstructured":"Pomykala KL, Czernin J, Grogan TR, Armstrong WR, Williams J, Calais J. Total-body 68Ga-PSMA-11 PET\/CT for bone metastases detection in prostate cancer patients: potential impact on bone scan guidelines. J Nucl Med. 2020;61:405\u201311.","journal-title":"J Nucl Med"},{"key":"5778_CR2","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","volume":"67","author":"ND James","year":"2015","unstructured":"James ND, Spears M, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with newly diagnosed metastatic prostate cancer in the \u201cdocetaxel era\u201d: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK\/06\/019). Eur Urol. 2015;67:1028\u201338.","journal-title":"Eur Urol"},{"key":"5778_CR3","doi-asserted-by":"crossref","unstructured":"Kesler M, Kerzhner K, Druckmann I, Kuten J, Levine C, Sarid D, et al. Staging 68Ga-PSMA PET\/CT in 963 consecutive patients with newly diagnosed prostate cancer: incidence and characterization of skeletal involvement. Eur J Nucl Med Mol Imaging. Epub ahead of print on 27 December 2021.","DOI":"10.21203\/rs.3.rs-975577\/v1"},{"key":"5778_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00520-014-2437-3","volume":"23","author":"MS Broder","year":"2015","unstructured":"Broder MS, Gutierrez B, Cherepanov D, Linhares Y. Burden of skeletal-related events in prostate cancer: unmet need in pain improvement. Support Care Cancer. 2015;23:237\u201347.","journal-title":"Support Care Cancer"},{"key":"5778_CR5","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502\u201312.","journal-title":"N Engl J Med"},{"key":"5778_CR6","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progression after docetaxel treatment: a randomized open-label trial. Lancet. 2010;376:1147\u201354.","journal-title":"Lancet"},{"key":"5778_CR7","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:686\u2013700.","journal-title":"Lancet Oncol"},{"key":"5778_CR8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424\u201333.","journal-title":"N Engl J Med"},{"key":"5778_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Foss\u00e5 SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323.","journal-title":"N Engl J Med"},{"key":"5778_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.116.183194","volume":"58","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Schmidt M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85\u201390.","journal-title":"J Nucl Med"},{"key":"5778_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00259-020-04797-9","volume":"48","author":"H Ahmadzadehfar","year":"2021","unstructured":"Ahmadzadehfar H, Rahbar K, Baum R, Seifert R, Kessel K, Bogemann M, et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicentre study (the 617 trial). Eur J Nuclear Med Mol Imaging. 2021;48:113\u201322.","journal-title":"Eur J Nuclear Med Mol Imaging"},{"key":"5778_CR12","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","volume":"75","author":"MM Heck","year":"2019","unstructured":"Heck MM, Tauber R, Schwaiger S, Retz M, D\u2019Alessandria C, Maurer T, et al. Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. Eur Urol. 2019;75:920\u20136.","journal-title":"Eur Urol"},{"key":"5778_CR13","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00259-021-05525-7","volume":"49","author":"F Khreish","year":"2022","unstructured":"Khreish F, Ghazal Z, Marlowe RJ, Rosar F, Sabet A, Maus S, et al. 177Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study). Eur J Nucl Med Mol Imaging. 2022;49:1075\u201385.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5778_CR14","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804.","journal-title":"Lancet"},{"key":"5778_CR15","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sator","year":"2021","unstructured":"Sator O, de Bono J, Chi KN, Fizazi K, Hermann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"key":"5778_CR16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2021.03.004","volume":"80","author":"MS Sadaghiani","year":"2021","unstructured":"Sadaghiani MS, Sheikhbahaei S, Werner RA, Pienta KJ, Pomper MG, Solnes LB, et al. A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer. Eur Urol. 2021;80:82\u201394.","journal-title":"Eur Urol"},{"key":"5778_CR17","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2174\/1874471011666180502104524","volume":"11","author":"A Morgenstern","year":"2018","unstructured":"Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F. An overview of targeted alpha therapy with 225actnium and 213bismuth. Curr Radiopharm. 2018;11:200\u20138.","journal-title":"Curr Radiopharm"},{"key":"5778_CR18","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, Weis N, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941\u20134.","journal-title":"J Nucl Med"},{"key":"5778_CR19","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","volume":"58","author":"C Kratochwil","year":"2017","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, et al. Targeted \u03b1-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58:1624\u201331.","journal-title":"J Nucl Med"},{"key":"5778_CR20","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2967\/jnumed.117.203539","volume":"59","author":"C Kratochwil","year":"2018","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, et al. Targeted \u03b1-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59:795\u2013802.","journal-title":"J Nucl Med"},{"key":"5778_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00259-018-4167-0","volume":"46","author":"M Sathekge","year":"2019","unstructured":"Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T, et al. 225Ac-PSMA-617 in chemotherapy-na\u00efve patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2019;46:129\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5778_CR22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2967\/jnumed.119.229229","volume":"61","author":"M Sathekge","year":"2020","unstructured":"Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Knoesen O, Mahapane J, et al. Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving 225Ac-PSMA-617 radioligand therapy. J Nucl Med. 2020;61:62\u20139.","journal-title":"J Nucl Med"},{"key":"5778_CR23","doi-asserted-by":"publisher","first-page":"9364","DOI":"10.7150\/thno.48107","volume":"23","author":"MP Yadav","year":"2020","unstructured":"Yadav MP, Ballal S, Sahoo RK, Tripathi M, Seth A, Bal C. Efficacy and Safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients. Theranostics. 2020;23:9364\u201377.","journal-title":"Theranostics"},{"key":"5778_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","volume":"79","author":"B Feuerecker","year":"2021","unstructured":"Feuerecker B, Tauber R, Knorr K, Heck M, Beheshti A, Sedl C, et al. Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA. Eur Urol. 2021;79:343\u201350.","journal-title":"Eur Urol"},{"key":"5778_CR25","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2967\/jnumed.120.251017","volume":"62","author":"MJ Zacherrl","year":"2021","unstructured":"Zacherrl MJ, Gildehaus FJ, Mittlmeier L, Boning G, Gosewisch A, Wenter V, et al. First clinical results for PSMA-targeted \u03b1-therapy using 225Ac-PSMA-I&T in advanced-mCRPC patients. J Nucl Med. 2021;62:669\u201374.","journal-title":"J Nucl Med"},{"key":"5778_CR26","doi-asserted-by":"crossref","unstructured":"Sathekge M, Bruchertseifer F, Vorster M, Lawal I, Knoesen O, Mahapane J, et al. mCRPC patients receiving 222Ac-PSMA-617 therapy in the post androgen deprivation therapy setting: response to treatment and survival analysis. J Nucl Med. Epub ahead of print on February 14, 2022.","DOI":"10.2967\/jnumed.121.263618"},{"key":"5778_CR27","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2967\/jnumed.117.190124","volume":"58","author":"U Haberkorn","year":"2017","unstructured":"Haberkorn U, Giesel F, Morgenstern A, Kratochwil C. The future of radioligand therapy: \u03b1, \u03b2, or Both? J Nucl Med. 2017;58:1017\u20138.","journal-title":"J Nucl Med"},{"key":"5778_CR28","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/MOU.0000000000000685","volume":"30","author":"IO Lawal","year":"2020","unstructured":"Lawal IO, Bruchertseifer F, Vorster M, Morgenstern A, Sathekge MM. Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer. Curr Opin Urol. 2020;30:98\u2013105.","journal-title":"Curr Opin Urol"},{"key":"5778_CR29","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/RLU.0000000000000870","volume":"40","author":"I Lawal","year":"2015","unstructured":"Lawal I, Vorster M, Boshomane T, Ololade K, Ebenhan T, Sathekge M. Metastatic prostate carcinoma presenting as a superscan on 68Ga-PSMA PET\/CT. Clin Nucl Med. 2015;40:755\u20136.","journal-title":"Clin Nucl Med"},{"key":"5778_CR30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00259-021-05434-9","volume":"49","author":"MM Sathekge","year":"2021","unstructured":"Sathekge MM, Bruchertseifer F, Vorster M, Morgenstern A, Lawal IO. Global experience with PSMA-based alpha therapy in prostate cancer. Eur J Nucl Med Mol Imaging. 2021;49:30\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5778_CR31","unstructured":"National Cancer Institute \u2013 Division of Cancer Treatment and Diagnosis. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Available from: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html. Accessed on 20 December 2021."},{"key":"5778_CR32","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1200\/JCO.1999.17.11.3461","volume":"17","author":"GJ Bubley","year":"1999","unstructured":"Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461\u20137.","journal-title":"J Clin Oncol"},{"key":"5778_CR33","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402\u201318.","journal-title":"J Clin Oncol"},{"key":"5778_CR34","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/1471-2407-10-284","volume":"10","author":"C Nieder","year":"2010","unstructured":"Nieder C, Haukland E, Pawinski A, Dalhuag A. Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases. BMC Cancer. 2010;10:284.","journal-title":"BMC Cancer"},{"key":"5778_CR35","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1007\/s00259-019-04354-z","volume":"46","author":"MM Sathekge","year":"2019","unstructured":"Sathekge MM, Bruchertseifer F, Lawal IO, Vorster M, Knoesen O, Lengana T, et al. Treatment of brain metastases of castration-resistant prostate cancer with 225Ac-PSMA-617. Eur J Nucl Med Mol Imaging. 2019;46:1756\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5778_CR36","first-page":"100038","volume":"3","author":"LC Maserumule","year":"2021","unstructured":"Maserumule LC, Mokoala KMG, Hlongwa KN, Ndlovu H, Reed JD, Ismail A, et al. Exceptional initial response of prostate cancer lung metastases to 225Ac-PSMA: A case report. Curr Probl Cancer: Case Rep. 2021;3:100038.","journal-title":"Curr Probl Cancer: Case Rep"},{"key":"5778_CR37","doi-asserted-by":"crossref","unstructured":"Gafita A, Wang H, Robertson A, Armstrong WR, Zaum R, Weber M, et al. Tumour sink effect in 68Ga-PSMA-11 PET: myth or reality? J Nucl Med. Epub ahead of print on 28 May 2021.","DOI":"10.2967\/jnumed.121.261906"},{"key":"5778_CR38","doi-asserted-by":"publisher","first-page":"55094","DOI":"10.18632\/oncotarget.19049","volume":"8","author":"FC Gaertner","year":"2017","unstructured":"Gaertner FC, Halabi K, Ahmadzadehfar H, Kurpig S, Eppard E, Kotsikopoulos C, et al. Uptake of PSMA-ligand in normal tissues is dependent on tumour load in patients with prostate cancer. Oncotarget. 2017;8:55094\u2013103.","journal-title":"Oncotarget"},{"key":"5778_CR39","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3390\/pharmaceutics13050699","volume":"13","author":"ECA van der Sar","year":"2021","unstructured":"van der Sar ECA, de Keizer B, Lam MGEH, Braat AJAT. Competition (\u2018steal\u2019 phenomenon) between [68Ga]Ga-PSMA-11 uptake in prostate tumour tissue versus healthy tissue. Pharmaceutics. 2021;13:699.","journal-title":"Pharmaceutics"},{"key":"5778_CR40","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825\u201333.","journal-title":"Lancet Oncol"},{"key":"5778_CR41","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2020.05.004","volume":"78","author":"A Gafita","year":"2020","unstructured":"Gafita A, Fendler WP, Hui W, Sandhu S, Weber M, Esfandiari R, et al. Efficacy and safety of 177Lu-labeled prostate-specific membrane antigen treatment in patients with diffuse bone marrow involvement: a multicentre retrospective study. Eur Urol. 2020;78:148\u201354.","journal-title":"Eur Urol"},{"key":"5778_CR42","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.3390\/cancers13164017","volume":"13","author":"D Groener","year":"2021","unstructured":"Groener D, Baumgarten J, Haefele S, Happel C, Klimek K, Mader N, et al. Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement. Cancers. 2021;13:4017.","journal-title":"Cancers"},{"key":"5778_CR43","doi-asserted-by":"publisher","first-page":"035016","DOI":"10.1088\/1361-6560\/abd3ef","volume":"66","author":"J Tranel","year":"2021","unstructured":"Tranel J, Feng FY, St James S, Hope TA. Effect of microdistribution of alpha and beta-emitters in targeted radionuclide therapies on delivered dose in a GATE model of bone marrow. Phys Med Biol. 2021;66:035016.","journal-title":"Phys Med Biol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05778-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-022-05778-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05778-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T11:04:18Z","timestamp":1658574258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-022-05778-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,6]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["5778"],"URL":"https:\/\/doi.org\/10.1007\/s00259-022-05778-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,6]]},"assertion":[{"value":"9 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed per the ethical standard of our institutions and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients gave written informed consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All patients provided informed consent to allow for the publication of their anonymized data collected during this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}